Turtle Creek Wealth Advisors LLC Acquires Shares of 181,700 MiMedx Group, Inc. (NASDAQ:MDXG)

Turtle Creek Wealth Advisors LLC bought a new stake in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 181,700 shares of the company's stock, valued at approximately $1,594,000. Turtle Creek Wealth Advisors LLC owned about 0.16% of MiMedx Group as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. raised its stake in MiMedx Group by 2.0% during the 2nd quarter. BlackRock Inc. now owns 8,118,485 shares of the company's stock valued at $53,663,000 after acquiring an additional 160,933 shares during the last quarter. Vanguard Group Inc. raised its stake in MiMedx Group by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 6,437,155 shares of the company's stock valued at $46,927,000 after acquiring an additional 250,812 shares during the last quarter. State Street Corp raised its stake in MiMedx Group by 6.0% during the 1st quarter. State Street Corp now owns 4,406,544 shares of the company's stock valued at $20,755,000 after acquiring an additional 250,334 shares during the last quarter. Geode Capital Management LLC raised its stake in MiMedx Group by 6.0% during the 2nd quarter. Geode Capital Management LLC now owns 2,331,277 shares of the company's stock valued at $15,410,000 after acquiring an additional 132,740 shares during the last quarter. Finally, Cannell Capital LLC raised its stake in MiMedx Group by 106.7% during the 3rd quarter. Cannell Capital LLC now owns 2,273,762 shares of the company's stock valued at $16,576,000 after acquiring an additional 1,173,506 shares during the last quarter. 79.15% of the stock is owned by hedge funds and other institutional investors.

MiMedx Group Stock Performance

NASDAQ MDXG traded up $0.12 on Tuesday, hitting $7.02. 496,757 shares of the company's stock were exchanged, compared to its average volume of 770,871. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.57 and a quick ratio of 3.11. The firm's 50-day moving average price is $7.89 and its two-hundred day moving average price is $7.67. MiMedx Group, Inc. has a fifty-two week low of $3.13 and a fifty-two week high of $9.27. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of 21.66 and a beta of 1.32.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its earnings results on Wednesday, February 28th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.08 by ($0.04). MiMedx Group had a net margin of 14.49% and a return on equity of 41.12%. The company had revenue of $86.83 million during the quarter, compared to analysts' expectations of $85.58 million. On average, research analysts expect that MiMedx Group, Inc. will post 0.33 EPS for the current year.

Insider Buying and Selling at MiMedx Group

In other news, COO Ricci S. Whitlow sold 15,271 shares of MiMedx Group stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $8.01, for a total transaction of $122,320.71. Following the sale, the chief operating officer now directly owns 401,050 shares of the company's stock, valued at $3,212,410.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CAO William Frank Iv Hulse sold 20,381 shares of the business's stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $7.95, for a total value of $162,028.95. Following the completion of the sale, the chief accounting officer now directly owns 479,959 shares of the company's stock, valued at $3,815,674.05. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Ricci S. Whitlow sold 15,271 shares of the business's stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $8.01, for a total value of $122,320.71. Following the completion of the sale, the chief operating officer now directly owns 401,050 shares of the company's stock, valued at $3,212,410.50. The disclosure for this sale can be found here. Insiders have sold 51,145 shares of company stock valued at $409,378 over the last three months. 19.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Lake Street Capital assumed coverage on MiMedx Group in a research note on Thursday, March 7th. They set a "buy" rating and a $12.00 price objective for the company. Mizuho boosted their target price on MiMedx Group from $13.00 to $14.00 and gave the stock a "buy" rating in a research report on Friday, March 1st. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $12.25.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.